Mehiläinen acquires InMedica Group, the largest private healthcare provider in Lithuania

InMedica Group is a medical network that offers primary, specialist, dental, and hospital care, as well as mental health services and diagnostics across Lithuania. InMedica Group serves a diverse range of patients, including individual customers, corporations, and those covered by public health insurance. With over 3,500 employees and 89 facilities, the company provides over 2.7 million physician visits annually and is a primary healthcare provider for more than 310,000 patients. InMedica Group’s revenue is expected to exceed EUR150 million in 2024. 

InMedica Group’s sellers are the leading private equity fund in the Baltics, INVL Baltic Sea Growth Fund, AB City, a private group of healthcare and pharmaceutical companies, and the private company Litgaja, controlled by InMedica’s founding entrepreneur, CEO Kęstutis Broniukaitis. The transaction is expected to be the largest healthcare services transaction in the history of Baltic mergers and acquisitions.

“This is a landmark transaction for our fund and its investors, as well as for the entire Lithuanian healthcare market. As a fund, we have fulfilled our mission – we have created the right conditions for a relatively small business to become a market leader and an integral part of the healthcare system. After evaluating potential investors, we believe that Mehiläinen is the best possible next owner for the InMedica Group, as it has exceptional resources, capabilities, and the corporate culture to support InMedica Group’s continued growth and development,” says Nerijus Drobavičus, partner at INVL Baltic Sea Growth Fund and Chairman of the Board at InMedica.

InMedica Group’s service portfolio and business model align closely with Mehiläinen’s, offering a solid foundation for future collaboration.

“InMedica Group is thrilled to join forces with Mehiläinen Group. Mehiläinen has been at the forefront of developing digital healthcare and is a trusted name in the industry. This partnership is an important milestone in our mission to improve healthcare services for patients in Lithuania,” comments InMedica Group CEO, Kęstutis Broniukaitis.

“The private healthcare market in Lithuania is growing rapidly, and InMedica Group is a high-quality market leader with an excellent reputation. I’m excited to work with Kęstutis and the management team. Together, we can continue the successful growth and further enhance the services provided,” comments Andreas Taalas, Mehiläinen Business Line Director for the Baltic region.

The transaction will not have a direct impact on InMedica Group’s personnel or patients, and the day-to-day operations will continue as usual, ensuring a seamless transition for all stakeholders. The transaction will enter into force on approval by the authorities. 

Additional media requests:
Mehiläinen, Andreas Taalas, contact through Mehiläinen communications: noora.hostikka@mehilainen.fi

InMedica Group, CEO Kęstutis Broniukaitis, contact through InMedica group communications:  ernesta.juodvirsiene@inmedica.lt

INVL Baltic Sea Growth Fund, Nerijus Drobavičius, contact through INVL Baltic Sea Growth Fund communications: virginija.zygiene@invl.com

AB City, contact through Repharm communications: liga.ribkinska@repharm.lv


Mehiläinen Group is a well-known and highly respected private provider of social care and healthcare services, offering comprehensive high-quality services in its home market, Finland, as well as in Sweden, Germany, and Estonia. Mehiläinen offers digital healthcare software solutions through its subsidiary, BeeHealthy. 115-year-old Mehiläinen is a rapidly developing and growing leader in the industry. It serves 2.1 million customers annually, and services are provided at 840 locations by more than 37,000 employees and private practitioners. Mehiläinen invests in the possibilities of digitalisation and the effectiveness and quality of care in all its business areas.

InMedica Group With a network of 89 facilities, including 84 clinics and 5 laboratories across 27 cities, InMedica Group is the largest private healthcare service provider in Lithuania. It is the owner of InMedica, Kardiolita Hospital, and VIC Dental Clinics. The InMedica Group’s companies offer a comprehensive range of medical services, including primary care, outpatient specialist care, surgery, dental care, diagnostic, and other medical services. InMedica Group’s companies have over 3,500 employees and provide healthcare services for more than 310,000 registered primary healthcare patients. In 2024 InMedica Group revenue is expected to exceed EUR 150 million.

INVL Baltic Sea Growth Fund With a size of EUR 165 million, the INVL Baltic Sea Growth Fund is the leading private equity fund in the Baltics. Its anchor investor is the European Investment Fund (EIF). The EIF, which is a part of the European Investment Bank, has committed EUR 30 million with the support of the European Fund for Strategic Investments (a key element of the Investment Plan for Europe, or the Junker Plan) while also allocating resources from the Baltic Innovation Fund, a “fund of funds” initiative developed in cooperation with the governments of Lithuania, Latvia and Estonia. The initiative aims to increase capital investment in high-growth potential small and medium-sized enterprises in the Baltics. The fund is managed by Invalda INVL group. The group’s companies manage or have under supervision more than EUR 1.6 billion of assets.

AB City is the parent company of two economically and socially significant joint-stock companies – Repharm and  Olpha. The group includes companies operating in healthcare services and laboratory testing, pharmaceutical retail and wholesale, the production of medicines and medical devices. The group’s companies are represented across the Baltic region and export medicines and medical devices to at least 60 countries worldwide. AB City’s development strategy is focused on investments in expanding high quality and innovative healthcare and laboratory services through Baltics and other European Union countries, while also broadening medicines product portfolio to strengthen Baltics pharmaceutical manufacturing capacities.